Global Tricuspid Valve Repair Market to Reach USD 2.5 Billion by 2028 Driven by Technological Advancements and Rising Prevalence of Heart Valve Disorders

The Global Tricuspid Valve Repair Market will reach US$2.5 billion by 2028. The global tricuspid repair market is driven by the increasing incidence of tricuspid disorders, advances in medical technology, increased awareness of heart valve diseases, a growing geriatric population and the preference for minimally invasive procedures like annuloplasty and transcatheter tricuspid repair (TTVR).

Browse market trends, size, share and growth report - request a sample copy: https://meditechinsights.com/tricuspid-valve-repair-market/request-sample/

The tricuspid is one of the four valves that controls blood flow in our heart. It is located on the right side, between the upper chambers (atrium) of our heart and the lower chambers (ventricle). It ensures blood flows in the right direction from the right ventricle down to the right atrium. The tricuspid has three flaps called leaflets, which open and close when blood flows through. Tricuspid valve disease is a term used to describe health conditions that affect tricuspid function. The main types include:

Tricuspid regurgitation: The valve leaks, or does not close tightly enough. This allows blood to leak in the opposite direction.

Tricuspid Stenosis - The valve leaflets are too stiff and can restrict blood flow.

The medical procedure of tricuspid valve repair and replacement is used to treat diseases that affect one of the four heart valves. It is usually better to repair a patient's heart valve than replace it with a prosthetic. Valve repair involves the surgeon altering the tissue or underlying structure of the mitral and tricuspid vales. An annuloplasty band or ring is used in nearly all valve repairs. It is a cloth-covered device implanted around or the annulus of the mitral valve or tricuspid. It supports the patient's mitral or tricuspid valve and brings the leaflets closer together to reduce leaks. This procedure can reduce symptoms and increase the survival rate of people with tricuspid regurgitation.

The market for tricuspid valve repair is driven by the advancement in managing tricuspid regurgitation.

Tricuspid regurgitation is the most common reason for tricuspid repair. In the United States, 1.6 million people suffer from moderate to severe tricuspid reflux. However, only a few hundred tricuspid repair procedures are performed each year. Patients are mostly elderly, with fatigue, a limited tolerance to exercise, peripheral oedema and abdominal swelling. These symptoms can be managed with conservative drugs such as diuretics at high doses, but the clinical effects are not significant. The tricuspid surgery is included in clinical guidelines that are authoritative, but its treatment rate and mortality rate are lower than other valvular disease. Less than 1% of patients undergo surgery due to co-morbidities. Most patients are only offered medical therapy in order to temporarily reduce volume overload. There is a growing demand for minimally-invasive procedures to treat tricuspid regurgitation. For example,

Edwards Lifesciences Corporation, in October 2023 announced that its EVOQUE tricuspid replacement system had received CE Marking for the transcatheter therapy of eligible patients with TR.

In April 2021 Abbott announced that it had received CE Mark certification for its next generation TriClip Transcatheter Tricuspid Valve Repair System. This is the first of its kind minimally invasive tricuspid valve repair device to be available in Europeto cure tricuspid regurgitation.

Tricuspid Valve Repair Market: Emerging Trends

The tricuspid valve market is experiencing a number of emerging trends.

Transcatheter Approaches There are a number of innovative technologies being investigated for transcatheter tricuspid repair, including leaflet coaptation and annuloplasty, as well as prosthetic valve deployment. Direct suture annuloplasty is a common technique for transcatheter tricuspid valve repair. Other techniques include direct ring annuloplasty and coaptation enhancement. For example,

Cardiac Implant LLC announced in September 2022 that its Annuloplasty Ring was successfully deployed with a therapeutic adjustment procedure utilizing its innovative Tri-Ring (tm) percutaneous device.

Clip Technologies: Companies such as Abbott have been working to develop innovative clip technologies. Abbott's TriClip is a minimally invasive, first-of-its kind device that was designed specifically for tricuspid valve repair. For example,

Abbott announced in May 2023 that it had late-breaking data which added to the clinical evidence that supports the benefits of the TriClip Transcatheter Edge-to-Edge Repair (TEER) System for treating patients with leaking tricuspid valvules.

Clinical Trials: The high level of investment by manufacturers in clinical trials and the introduction of new devices offer numerous growth opportunities to market players. Research aimed at understanding the pathology behind tricuspid disease is helping to develop targeted and effective treatment options.

Medtronic plc announced that the FDA approved an early feasibility study of the Intrepid Transcatheter Tricuspid Valve Replacement System (TTVR) in September 2020 for patients with severe symptoms of tricuspid regurgitation.

Bioprosthetic Valves. An increasing number patients who undergo tricuspid replacement (TVR), have received bioprostheses because of their durability in the tricuspid location and the benefit of removing anticoagulant medication from the patients.

Tricuspid Valve Repair Market: Key Constraints/Challenges

The tricuspid repair market is faced with several challenges and constraints. Costs associated with cardiac surgery, including tricuspid repair procedures, can be high. Tricuspid repair or replacement can be invasive, and it comes with several risks and complications, including heart blocks, infections and bleeding, prosthetic valve malfunction, stroke and death. Tricuspid repair requires a high level of expertise and specialized skills. The availability of alternative treatments or devices for tricuspid disorders could also impact the market growth.

North America accounts for the largest share of the global market

North America is the leading global market for tricuspid repair. The region is experiencing substantial market growth. This is due to favorable regulatory environments that allow for the approval and marketing of innovative tricuspid repair devices. An increase in the prevalence and severity of cardiovascular diseases including valvular disorder, as well as the aging population and technological advancements, all contribute to this growth. The European region will experience a lucrative growth over the forecast period. The tricuspid repair market in Europe is expected to grow significantly due to the advancements in healthcare infrastructure and the growing awareness of heart valve diseases.

Tricuspid Valve Repair Market: Competitive Landscape

The top market players in the global tricuspid valve repair market include Edwards Lifesciences Corp., Abbott, Medtronics, Corcym, Labcor, Valtech Cardio Ltd., Sorin S.p.A., CroiValve, FOLDAX, Cardia Implant LLC, LivaNova PLC, Cyberonics Inc., Boston Scientific Corporation, Micro Interventional Devices Inc., 4Tech Inc., among others.

Explore the latest trends and deep insights in just one click: https://meditechinsights.com/tricuspid-valve-repair-market/

Organic and Inorganic Growth Strategies Adopted by Players to Establish Their Foothold in the Market

Players operating in this market are adopting both organic and inorganic growth strategies such as collaborations, and acquisitions to garner market share. For instance,

In April 2023, Corcym, announced the acquisition of the BioStable Science & Engineering assets including the HAART Aortic Annuloplasty Devices, the world's only aortic internal annuloplasty devices designed for use during valve repair for aortic insufficiency

In August 2022, Edwards Lifesciences Corporation, announced the company's PASCAL Precision transcatheter valve repair system received a CE Mark for the treatment of mitral and tricuspid regurgitation (MR and TR)
In February 2022, CroíValve, a Dublin-based medical device company raised euro8M Series A funding to fund a feasibility clinical study with its DUO Coaptation Valve system

The tricuspid valve repair market is a dynamic and evolving field. The market is expected to grow due to advancements in transcatheter tricuspid valve repair technologies, growing clinical trials, and aggressive organic and inorganic growth strategies followed by the players.

Top Related Reports:

Cardiac Catheterization Market: https://meditechinsights.com/cardiac-catheterization-market/

Structural Heart Devices Market: https://meditechinsights.com/structural-heart-devices-market/

Transcatheter Mitral Valve Replacement (TMVR) Market: https://meditechinsights.com/transcatheter-mitral-valve-replacement-tmvr-market/

Contact:

Ruta Halde
Associate, Medi-Tech Insights
Phone: +32 498 86 80 79
Email: info@meditechinsights.com
Website: https://meditechinsights.com/

About Medi-Tech Insights

Medi-Tech Insights is a healthcare-focused business research & insights firm. Our clients include Fortune 500 companies, blue-chip investors & hyper-growth start-ups. We have completed 100+ projects in Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma Services in the areas of market assessments, due diligence, competitive intelligence, market sizing and forecasting, pricing analysis & go-to-market strategy. Our methodology includes rigorous secondary research combined with deep-dive interviews with industry-leading CXO, VPs, and key demand/supply side decision-makers.

This release was published on openPR.